Input parameters used for the ICER adjustment methods
| Parameters | ₹ | $ | Reference |
| Simple adjustment (payer’s perspective) | |||
| ICERo (<12 years old) | −344 673 971 | −4 190 565 | ICER report |
| ICERo (≥12 years old) | −806 100 255 | −9 800 611 | ICER report |
| Simple adjustment parameters (societal perspective) | |||
| ICERo (<12 years old) | 360 754 763 | 4 386 076 | ICER report |
| ICERo (≥12 years old) | 838 631 936 | 10 196 133 | ICER report |
| Cost parameters | |||
| PA (drug price in India) for 30 mg/mL (as of 19 April 2023) | 58 900 | Manufacturer (Roche Medical Information) | |
| Po (drug price in USA) for 30 mg/mL (as of 19 April 2023) | 282 499 | 3435 | www.drugs.com/price-guide/hemlibra |
| PA (drug price in India) for 150 mg/mL (as of 19 April 2023) | 294 392 | Manufacturer (Roche Medical Information) | |
| Po (drug price in USA) for 150 mg/mL (as of 19 April 23) | 1 409 369 | 17 135.18 | www.drugs.com/price-guide/hemlibra |
| Cost parameters for moderate adjustment | |||
| Cost of EMI per vial (30 mg/mL) | 58 900 | Manufacturer (Roche Medical Information) | |
| Mean dose per kilogram body weight (mg/kg) per month | 6 | Expert opinion | |
| Mean weight of patients on prophylaxis (kg), 2–5 years | 12 | Expert opinion | |
| Mean weight of patients on prophylaxis (kg), 6–10 years | 25 | Expert opinion | |
| Mean weight of patients on prophylaxis (kg), 6–10 years | 44 | Expert opinion | |
| Mean duration of treatment (in months) (Mi) | 420 | Expert opinion | |
| Cost of BPA per vial (500 IU) | 80 000 | Expert opinion | |
| Mean duration of patients on FEIBA (Factor eight inhibitor bypass activity) regimen (in months) (Mc) | 300 | Expert opinion | |
| Dose per kilogram body weight (IU) | 500 | Expert opinion | |
| Frequency of administration (per day) | 2 | Expert opinion | |
| Approximate number of bleeding episodes per month | 2 | Expert opinion | |
| Complex adjustment | |||
| PPP GDP for study country (USA) | 59 915 | World Bank data | |
| PPP GDP for study country (India) | 6112.0 | World Bank data | |
| Consumer Price Index (CPI) for health in India for current year (2023) | 183.4 | MOSPI, Government of India | |
| CPI for health in India for publication year (2018) | 135.2 | MOSPI, Government of India | |
| Life expectancy from birth in study country (USA) | 78.54 | World Bank data | |
| Life expectancy from birth in India | 70.47 | World Bank data | |
| Reduction in life expectancy (in years) | 10 | Expert opinion | |
| Life expectancy from disease in study country (2017) | 68.54 | Calculated | |
| Life expectancy from disease in India (2017) | 60.47 | Calculated | |
| Health system perspective | |||
| Emicizumab prophylaxis (≥12 years old) | 19 221 932 | ICER report | |
| No prophylaxis (≥12 years old) | 28 135 154 | ICER report | |
| Emicizumab prophylaxis (<12 years old) | 20 683 787 | ICER report | |
| No prophylaxis (<12 years old) | 31 012 935 | ICER report | |
| Societal perspective | |||
| Emicizumab prophylaxis (≥12 years old) | 19 623 275 | ICER report | |
| No prophylaxis (≥12 years old) | 28 901 756 | ICER report | |
| Emicizumab prophylaxis (<12 years old) | 21 212 892 | ICER report | |
| No prophylaxis (<12 years old) | 31 695 614 | ICER report | |
| Study-reported QALYs (2017) | |||
| Emicizumab prophylaxis (≥12 years old) | 15.41 | ICER report | |
| No prophylaxis (≥12 years old) | 14.5 | ICER report | |
| Emicizumab prophylaxis (<12 years old) | 22.79 | ICER report | |
| No prophylaxis (<12 years old) | 20.4 | ICER report | |
BPA, bypassing agent; EMI, emicizumab; GDP, gross domestic product; ICER, incremental cost-effectiveness ratio; PPP, purchasing power parity; QALY, quality-adjusted life year.